Novo Nordisk Investigational Site

Braunschweig 38118

0 studies enrolling now · 3 studies all time

What they study most

Congenital Bleeding Disorder, Congenital FXIII Deficiency, Haemophilia A

Studies at this site

• Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A — Completed
• Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 — Completed
• Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency — Completed